Summary

Location
at UCLA
Dates
study started
completion around

Description

Summary

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Keywords

Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Venetoclax, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Non-Hodgkin Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Eligibility

You can join if…

  • Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
  • Male subject agrees to refrain from sperm donation.
  • Female subjects must not be pregnant or breastfeeding.

You CAN'T join if...

  • None.

Locations

  • UCLA Santa Monica Hematology Oncology /ID# 210551
    Los Angeles California 90095 United States
  • University of Arizona Cancer Center - Tucson /ID# 210548
    Tucson Arizona 85724 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
Related Info
ID
NCT03844048
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 165 people participating
Last Updated